- Conditions
- Small-cell Lung Cancer, Large Cell Neuroendocrine Carcinoma of the Lung, Extrapulmonary Small Cell Carcinoma
- Interventions
- Abemaciclib,
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 2,099
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pain
- Interventions
- Relief Product Placebo Control, Relief Active Product 1, Relief Active Product 2, Relief Active Product 3
- Dietary Supplement
- Lead sponsor
- Radicle Science
- Industry
- Eligibility
- 21 Years to 105 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Del Mar, California
- Conditions
- Fructan Intolerance
- Interventions
- Sacrosidase Oral Solution, Placebo
- Drug
- Lead sponsor
- QOL Medical, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Asthma, COPD
- Interventions
- n-acetylcystine (NAC)+ albuterol, AeroEclipse-VersaPAP System
- Drug · Device
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Acute Myocardial Infarction Type 1
- Interventions
- Deferiprone Tablets, Placebo
- Drug
- Lead sponsor
- Rohan Dharmakumar
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana • Minneapolis, Minnesota
- Conditions
- Myelodysplastic Syndrome
- Interventions
- ON 01910.Na
- Drug
- Lead sponsor
- Traws Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 2
- States / cities
- Tampa, Florida • New York, New York
- Conditions
- Dementia, Alzheimer Type
- Interventions
- Xanamem™, Placebo (for Xanamem™)
- Drug
- Lead sponsor
- Actinogen Medical
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 14
- States / cities
- Tucson, Arizona • Los Angeles, California • Poway, California + 11 more
- Conditions
- HIV Infections
- Interventions
- Zidovudine, Zalcitabine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 3 Months to 12 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1995
- U.S. locations
- 44
- States / cities
- Long Beach, California • Los Angeles, California • Oakland, California + 29 more
- Conditions
- Lumbar Post-Laminectomy Syndrome, Chronic Low Back Pain, Vertebral Compression Fracture, Failed Back Surgery Syndrome
- Interventions
- Continuous intrathecal prognostic infusion test, Bupivacaine, Fentanyl, Placebo, Intrathecal Drug Delivery System (IDDS)
- Other · Drug · Device
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Methamphetamine Use Disorder
- Interventions
- Methamphetamine, Methylphenidate, Placebo oral capsule, Duloxetine
- Drug
- Lead sponsor
- Craig Rush
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 2
- States / cities
- Lexington, Kentucky
- Conditions
- Malignancies Including Melanoma, Kidney, Lung, Colorectal, Prostate, Neuroendocrine Tumor
- Interventions
- rSIFN-co
- Biological
- Lead sponsor
- Sichuan Huiyang Life Science and Technology Corporation
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Chicago, Illinois • Saint Paul, Minnesota
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Maraviroc, Maraviroc Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 21
- States / cities
- Huntington Beach, California • San Francisco, California • Hamden, Connecticut + 14 more
- Conditions
- Tobacco-Related Carcinoma
- Interventions
- Behavioral Intervention, Informational Intervention, Nicotine Replacement, Telephone-Based Intervention
- Behavioral · Other · Drug
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Alcoholism, Alcohol Abuse, Alcohol Dependence
- Interventions
- Dutasteride, Placebo
- Drug
- Lead sponsor
- UConn Health
- Other
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Farmington, Connecticut
- Conditions
- Scleroderma
- Interventions
- atorvastatin, Placebo
- Drug
- Lead sponsor
- Robyn T. Domsic, MD, MPH
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Classical Hodgkin Lymphoma
- Interventions
- CD30.CAR-EBVST cells
- Biological
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 12 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2040
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Cataract
- Interventions
- Dextenza 0.4Mg Ophthalmic Insert, Topical prednisolone acetate
- Drug
- Lead sponsor
- Vance Thompson Vision
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Sioux Falls, South Dakota
- Conditions
- Gingival Inflammation
- Interventions
- BLXA4, Placebo oral rinse
- Drug
- Lead sponsor
- The Forsyth Institute
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
- Conditions
- Stem Cell Surveillance
- Interventions
- Anthocyanin-rich berry extract, Anthocyanin-rich flower/leaf extract, Berry /leaf blend, Placebo
- Dietary Supplement
- Lead sponsor
- Natural Immune Systems Inc
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Klamath Falls, Oregon
- Conditions
- Traumatic Brain Injury
- Interventions
- 1 gram Tranexamic Acid (TXA), 2 grams TXA, 0.9% Sodium Chloride injectable
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 15 Years and older
- Enrollment
- 967 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Minneapolis, Minnesota • Rochester, Minnesota + 7 more
- Conditions
- Hepatitis C, Heroin Dependence
- Interventions
- Buprenorphine/naloxone, pegInterferon
- Drug
- Lead sponsor
- National Institute on Drug Abuse (NIDA)
- NIH
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- Oakland, California
- Conditions
- Neovascular Age-Related Macular Degeneration (nAMD)
- Interventions
- 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)
- Biological
- Lead sponsor
- 4D Molecular Therapeutics
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 60
- States / cities
- Scottsdale, Arizona • Sun City, Arizona • Tucson, Arizona + 55 more
- Conditions
- Macular Edema Secondary to Retinal Vein Occlusion
- Interventions
- Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose, Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg, Sham, Fluorescein
- Drug · Diagnostic Test
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 892 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 53
- States / cities
- Fullerton, California • Long Beach, California • Mountain View, California + 48 more
- Conditions
- Advanced Solid Tumors
- Interventions
- VVD-159642, Sotorasib, Trametinib
- Drug
- Lead sponsor
- Vividion Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 7
- States / cities
- Grand Rapids, Michigan • Austin, Texas • Irving, Texas + 3 more